At the 2026 SCOPE Summit, Scott Megaffin, CEO of Adiso Therapeutics, detailed a transition from the economic ebb of recent years toward a flow characterized by disciplined momentum. This new phase for biotechnology follows a year of stabilization in 2025, where easing inflation and a robust finish for mid-sized public companies set the stage for a period of growth centered on clinical and operational execution.
The Emergence of a 90s-Like Economic Backdrop
The current macroeconomic landscape suggests the arrival of an environment reminiscent of the 1990s, where growth is pursued through a steady, disciplined approach. While 2024 was marked by pandemic-related downturns and regulatory uncertainty regarding new administrative leadership at the FDA, 2025 saw a resurgence in market confidence. Biotech regained significant momentum in the latter half of the year, outperforming many other indices as the industry gained clarity on the regulatory front.
Analysis of recent financial trends indicates that capital access is beginning to normalize, particularly for public entities. In the final quarter of 2025 alone, mid-sized public companies successfully added $4 billion in additional capital to their balance sheets. This influx of liquidity serves as a precursor for 2026, where capital access is expected to improve modestly for private companies. However, the panel suggested that this market will be highly selective, favoring products and programs with strong clinical data while assets that do not meet high-quality benchmarks may continue to lag or disappear.
Strategic Response to Geopolitical Shifts and Global Competition
A significant development underscored during the session is the rapid acceleration of the Chinese biopharmaceutical sector. Data presented indicated that Chinese production and early-stage development took off sharply in 2025, driven by improved speed within their regulatory authorities and a high degree of scientific innovation. This growth has created a new competitive pressure for traditional biotech hubs like Boston, as Chinese programs increasingly mimic and then advance upon Western innovation.
To remain competitive, the discussion highlighted the necessity for U.S. and European companies to rethink their global integration. Experts noted that many organizations are now leveraging Chinese clinical sites for faster patient enrollment, particularly in pivotal trials. The relationship is becoming increasingly bi-directional; Chinese firms are actively seeking to out-license assets back to the U.S. while simultaneously looking for novel Western assets to develop within their own borders. This globalized effort requires Western biopharma to maintain a high level of stealth mode regarding early-stage intellectual property, with some CEOs indicating they may reduce scientific conference presentations to protect their competitive edge.
Operational Excellence Through AI and Pipeline Discipline
For small-to-mid-sized biopharma companies, the path forward involves forging smart partnerships and maintaining rigorous pipeline discipline. Rather than holding assets until late-stage pivotal events, leaders are encouraged to seek early partnerships to bridge funding gaps. This discipline often requires the difficult decision to deprioritize certain assets to ensure that resources are concentrated on high-value programs.
Artificial intelligence (AI) has moved beyond a buzzword to become a core component of operational excellence. While initial adoption focused on regulatory document review and manufacturing (CMC) filings, the next wave of AI integration involves deep clinical application. For example, Adiso Therapeutics has partnered with the University of Michigan to apply machine learning to inflammatory bowel disease (IBD) research. By using AI to assess whole-colonal improvements of lesions rather than relying on single-lesion scoring, companies can provide a more comprehensive view of drug efficacy to potential partners. Large-scale industry moves, such as the partnership between Eli Lilly and Nvidia to build an AI lab, signal that AI is now a foundational requirement for any service provider or developer seeking to differentiate themselves.
Future Outlook: Stabilization and the Year of the Horse
As the industry moves deeper into 2026—metaphorically referred to as the Year of the Horse—the focus will remain on speed, execution, and timing. The market is expected to undergo an intense bifurcation between the haves and the have-nots. Companies that possess leverageable, high-quality assets and a clear path to execution will find themselves well-positioned for recapitalization and alternative exits beyond the traditional IPO route, which remains modest in its availability.
The broader implications for the clinical research ecosystem suggest that stabilization is the primary theme for the year. While the bumper year of 2019 remains a historical high point, the re-emergence of M&A activity—exemplified by the acquisition of weight-loss companies like Madrigal—indicates that big pharma is once again looking to small biopharma to replenish their pipelines. Success in this environment will depend on the ability to navigate geopolitical shifts, adopt transformative technology, and maintain the strategic foresight necessary to convert innovative science into market-ready therapies.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
